Form D · Pharmaceuticals

Spine BioPharma, Inc.

New York, NY · CIK 0001852647

Offering snapshot reported Jun 5, 2026 · SEC filing

Reported sold
$385K
Offering amount: $8.5M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 22, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 5, 2026Initial$384,798No comparison3SEC filing
Dec 18, 2024Initial$13,505,000No comparison10SEC filing
Oct 11, 2023Initial$2,399,629No comparison3SEC filing
Aug 31, 2023Initial$1,900,000No comparison1SEC filing
Feb 8, 2023Initial$13,000,000No comparison8SEC filing
Mar 24, 2022Initial$12,999,991No comparison6SEC filing
Apr 20, 2021Initial$3,000,000No comparison1SEC filing
Mar 22, 2021Initial$5,000,515No comparison14SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-586448

Source: Form D, filed Jun 5, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thomas Bumol, Ph D Director
Frank Cammisa, Md Director
Jason Gallagher Executive
Fran Magee Executive
Marc R. Viscogliosi Director, Executive
John J. Viscogliosi Director
Llc Viscogliosi Brothers, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
505 Park Avenue, 14 Th Floor
New York, NY, 10022
Phone: 212-583-9700